SEATTLE, March 14, 2018 – Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer…
Modern therapies targeting the immune synapse
We create modern, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases.
Alpine Immune Sciences (AIS) was founded in 2015 by experts in the field of recombinant, protein-based immunotherapies. Alpine capitalizes on our unique understanding of the immune synapse, evolving native proteins for therapeutic benefit.